LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-11820-x

By:

• van Tilburg, Cornelis M.;
• Kilburn, Lindsay B.;
• Perreault, Sébastien;
• Schmidt, Rene;
• Azizi, Amedeo A.;
• Cruz-Martínez, Ofelia;
• Zápotocký, Michal;
• Scheinemann, Katrin;
• Meeteren, Antoinette Y. N. Schouten-van;
• Sehested, Astrid;
• Opocher, Enrico;
• Driever, Pablo Hernáiz;
• Avula, Shivaram;
• Ziegler, David S.;
• Capper, David;
• Koch, Arend;
• Sahm, Felix;
• Qiu, Jiaheng;
• Tsao, Li-Pen;
• Blackman, Samuel C.

Publication type:

Article